{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:22:53Z","timestamp":1792635773694,"version":"4.5.0"},"reference-count":141,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9380\/A18084"],"award-info":[{"award-number":["C9380\/A18084"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Western world. MASLD-HCC can develop at an earlier stage of fibrosis compared to other causes of chronic liver disease, presenting challenges in how to risk-stratify patients to set up effective screening programmes. Therapeutic decision making for MASLD-HCC is also complicated by medical comorbidities and disease presentation at a later stage. The response to treatment, particularly immune checkpoint inhibitors, may vary by the aetiology of the disease, and, in the future, patient stratification will be key to optimizing the therapeutic pathways.<\/jats:p>","DOI":"10.3390\/cancers16020259","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:21:38Z","timestamp":1704691298000},"page":"259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges"],"prefix":"10.3390","volume":"16","author":[{"given":"Anju G. S.","family":"Phoolchund","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim I.","family":"Khakoo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"ref_1","first-page":"101133","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"29","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","unstructured":"(2023, November 26). World Health Organization Obesity and Overweight. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of Liver Transplantation for Non-Alcoholic Steatohepatitis: A European Liver Transplant Registry Study","volume":"71","author":"Haldar","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wainwright, P., and Byrne, C.D. (2016). Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030367"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease\u2014Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Targher, G., Byrne, C.D., and Tilg, H. (2020). NAFLD and Increased Risk of Cardiovascular Disease: Clinical Associations, Pathophysiological Mechanisms and Pharmacological Implications. Gut, 1691\u20131705.","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Taverna, A., Cappelli, D., Beatrice, G., Csermely, A., Sani, E., Byrne, C.D., and Targher, G. (2022). Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012481"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A Multisystem Disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13930","DOI":"10.1038\/ncomms13930","article-title":"The Immunoreceptor NKG2D Promotes Tumour Growth in a Model of Hepatocellular Carcinoma","volume":"8","author":"Sheppard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis Stage Is the Strongest Predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2014","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-Alcoholic Fatty Liver Disease-Related Risk of Cardiovascular Disease and Other Cardiac Complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD Progression from Steatosis to Fibrosing-Steatohepatitis Using Paired Biopsies: Implications for Prognosis and Clinical Management","volume":"62","author":"Mcpherson","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The Effect of the Magnitude of Weight Loss on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. Resistance Exercise in Non-Alcoholic Fatty Liver Disease: A Systematic Review","volume":"66","author":"Hashida","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular Actions and Clinical Outcomes with Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"i4428","DOI":"10.1136\/bmj.i4428","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD): Assessment and Management NICE Guideline","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10741-021-10079-9","article-title":"SGLT2 Inhibitors: A Focus on Cardiac Benefits and Potential Mechanisms","volume":"27","author":"Nikolic","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV Eradication Induced by Direct-Acting Antiviral Agents Reduces the Risk of Hepatocellular Carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-Based Risk Factors and Resource Utilization for HCC: US Perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_31","first-page":"4","article-title":"Mansour Bahardoust, 4 Predictors of 5 Year Survival Rate in Hepatocellular Carcinoma Patients","volume":"24","author":"Sarveazad","year":"2019","journal-title":"J. Res. Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"SYSTEMATIC REVIEWS AND META-ANALYSES Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review","volume":"10","author":"White","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dmrr.1291","article-title":"Diabetes Mellitus and Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"28","author":"Wang","year":"2012","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_37","first-page":"291546","article-title":"Obesity as a Major Risk Factor for Cancer","volume":"2013","author":"Silvestris","year":"2013","journal-title":"J. Obes."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1634\/theoncologist.2012-0066","article-title":"Body Mass Index and Risk of Primary Liver Cancer: A Meta-Analysis of Prospective Studies","volume":"17","author":"Wang","year":"2012","journal-title":"Oncologist"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1038\/srep09284","article-title":"Association between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-Analysis of the Influence of I148M Variant of Patatin-like Phospholipase Domain Containing 3 Gene (PNPLA3) on the Susceptibility and Histological Severity of Nonalcoholic Fatty Liver Disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 Rs738409 C > g Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/hepr.12840","article-title":"Development of Hepatocellular Carcinoma in Japanese Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease: Association between PNPLA3 Genotype and Hepatocarcinogenesis\/Fibrosis Progression","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-Analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant Rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of Hepatic Mboat7 Leads to Liver Fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 Rs641738 Variant and Hepatocellular Carcinoma in Non-Cirrhotic Individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 Rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease","volume":"61","author":"Dongiovanni","year":"2014","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ioannou, G.N., Green, P., Lowy, E., Mun, E.J., and Berry, K. (2018). Differences in Hepatocellular Carcinoma Risk, Predictors and Trends over Time According to Etiology of Cirrhosis. PloS ONE, 13.","DOI":"10.1371\/journal.pone.0204412"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-Scale Long-Term Follow-Up Study of Japanese Patients with Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis","volume":"51","author":"Ascha","year":"2007","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between Non-Alcoholic Fatty Liver Disease and Cancer Incidence Rate","volume":"68","author":"Kim","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated with Nonalcoholic Fatty Liver Disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cgh.2011.01.023","article-title":"Characteristics of Patients with Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma","volume":"9","author":"Yasui","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular Cancer: The Impact of Obesity, Type 2 Diabetes and a Multidisciplinary Team","volume":"60","author":"Dyson","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The Story of HCC in NAFLD: From Epidemiology, across Pathogenesis, to Prevention and Treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgw118","article-title":"Frequently Mutated Genes\/Pathways and Genomic Instability as Prevention Targets in Liver Cancer","volume":"38","author":"Rao","year":"2017","journal-title":"Carcinogenesis"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Donati, B., and Valenti, L. (2016). Telomeres, NAFLD and Chronic Liver Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030383"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41379-019-0218-8","article-title":"Detection of DNA Damage Response in Nonalcoholic Fatty Liver Disease via P53-Binding Protein 1 Nuclear Expression","volume":"32","author":"Akazawa","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1038\/s41467-021-24734-0","article-title":"CD8+ Tissue-Resident Memory T Cells Promote Liver Fibrosis Resolution by Inducing Apoptosis of Hepatic Stellate Cells","volume":"12","author":"Koda","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD Causes Selective CD4+ T Lymphocyte Loss and Promotes Hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3389\/fimmu.2019.01255","article-title":"Retained NK Cell Phenotype and Functionality in Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Stiglund","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_68","first-page":"322","article-title":"Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease","volume":"12","author":"Delgado","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","article-title":"Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular Characterisation of Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.26323","article-title":"The MTOR Pathway in Hepatic Malignancies","volume":"58","author":"Bhat","year":"2013","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.30697","article-title":"The MTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans HHS Public Access","volume":"70","author":"Xu","year":"2019","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hep.22033","article-title":"Etiology-Dependent Molecular Mechanisms in Human Hepatocarcinogenesis","volume":"47","author":"Schlaeger","year":"2008","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/carcin\/bgi378","article-title":"Activation of the Hedgehog Pathway in Human Hepatocellular Carcinomas","volume":"27","author":"Huang","year":"2006","journal-title":"Carcinogenesis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11670-012-0271-z","article-title":"Activation of Sonic Hedgehog Signaling Pathway Is an Independent Potential Prognosis Predictor in Human Hepatocellular Carcinoma Patients","volume":"24","author":"Che","year":"2012","journal-title":"Chin. J. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cheng, J.T., Wang, L., Wang, H., Tang, F.R., Cai, W.Q., Sethi, G., Xin, H.W., and Ma, Z. (2019). Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition. Cells, 8.","DOI":"10.3390\/cells8101178"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Weinmann, A., Alt, Y., Koch, S., Nelles, C., D\u00fcber, C., Lang, H., Otto, G., Zimmermann, T., Marquardt, J.U., and Galle, P.R. (2015). Treatment and Survival of Non-Alcoholic Steatohepatitis Associated Hepatocellular Carcinoma. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1197-x"},{"key":"ref_81","first-page":"73","article-title":"Comparing Clinical Presentations, Treatments and Outcomes of Hepatocellular Carcinoma Due to Hepatitis C and Non-Alcoholic Fatty Liver Disease","volume":"110","author":"Than","year":"2017","journal-title":"QJM Int. J. Med."},{"key":"ref_82","unstructured":"(2023, November 26). EASL Policy Statement Risk-Based Surveillance for Hepatocellular Carcinoma among Patients with Cirrhosis POLICY STATEMENT. Available online: https:\/\/easl.eu\/publication\/easl-policy-statement-risk-based\/."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B Predicts the Risk of Developing Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B on 5-Year Antiviral Therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jhep.2015.05.019","article-title":"Can We Use HCC Risk Scores to Individualize Surveillance in Chronic Hepatitis B Infection?","volume":"63","author":"Wong","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Lewinska, M., Santos-Laso, A., Arretxe, E., Alonso, C., Zhuravleva, E., Jimenez-Ag\u00fcero, R., Eizaguirre, E., Pareja, M.J., Romero-G\u00f3mez, M., and Jimenez, M.A. (2021). The Altered Serum Lipidome and Its Diagnostic Potential for Non-Alcoholic Fatty Liver (NAFL)-Associated Hepatocellular Carcinoma: Diagnosis of NAFLD-HCC Utilising Serum Lipidomics. EBioMedicine, 73.","DOI":"10.1016\/j.ebiom.2021.103661"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models Estimating Risk of Hepatocellular Carcinoma in Patients with Alcohol or NAFLD-Related Cirrhosis for Risk Stratification with Alcohol or NAFLD-Related Cirrhosis for Risk Stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients with Nonalcoholic Steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating Tumor DNA: Current Challenges for Clinical Utility","volume":"132","author":"Dang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality Standards for the Management of NAFLD: Consensus Recommendations from the British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG) NAFLD Special Interest Group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2018.12.014","article-title":"Association between Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study","volume":"70","author":"Baumeister","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCRESAHA.118.313348","article-title":"The Mediterranean Diet and Cardiovascular Health: A Critical Review","volume":"124","author":"Gea","year":"2019","journal-title":"Circ. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"716783","DOI":"10.3389\/fnut.2021.716783","article-title":"Dietary Interventions in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"8","author":"Houttu","year":"2021","journal-title":"Front. Nutr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic Review with Meta-Analysis: Bariatric Surgery Reduces the Incidence of Hepatocellular Carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11605-018-4004-6","article-title":"Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis","volume":"23","author":"Li","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/mc.22231","article-title":"Pioglitazone, a PPAR\u03b3 Agonist, Inhibits Growth and Invasion of Human Hepatocellular Carcinoma via Blockade of the Rage Signaling","volume":"54","author":"Yang","year":"2015","journal-title":"Mol. Carcinog."},{"key":"ref_97","first-page":"1606","article-title":"The Role of Thiazolidinediones in Hepatocellular Carcinoma Risk Reduction: A Population-Based Cohort Study in Taiwan","volume":"7","author":"Huang","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"154780","DOI":"10.1016\/j.metabol.2021.154780","article-title":"Thiazolidinediones, Alpha-Glucosidase Inhibitors, Meglitinides, Sulfonylureas, and Hepatocellular Carcinoma Risk: A Meta-Analysis","volume":"120","author":"Arvind","year":"2021","journal-title":"Metabolism"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"E19833","DOI":"10.1097\/MD.0000000000019833","article-title":"Association of Hepatocellular Carcinoma with Thiazolidinediones Use: A Population-Based Case-Control Study","volume":"99","author":"Lai","year":"2020","journal-title":"Medicine"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yang, C.T., Yao, W.Y., Yang, C.Y., Peng, Z.Y., Ou, H.T., and Kuo, S. (2023). Lower Risks of Cirrhosis and Hepatocellular Carcinoma with GLP-1RAs in Type 2 Diabetes: A Nationwide Cohort Study Using Target Trial Emulation Framework. J. Intern. Med.","DOI":"10.1111\/joim.13751"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Kim, T.S., Lee, M., Park, M., Kim, S.Y., Shim, M.S., Lee, C.Y., Choi, D.H., and Cho, Y. (2021). Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting MTOR Complex 1. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810027"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the Prevention of Hepatocellular Carcinoma in Diabetic Patients: A Systematic Review","volume":"19","author":"Cunha","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2011-301708","article-title":"Metformin Decreases Hepatocellular Carcinoma Risk in a Dose-Dependent Manner: Population-Based and in Vitro Studies","volume":"62","author":"Chen","year":"2013","journal-title":"Gut"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins Are Associated with a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., El Aziz, M.A.A., Singh, S., Pusceddu, S., Milione, M., Giacomelli, L., and Sacco, R. (2020). Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12040874"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.cgh.2020.08.026","article-title":"Effects of Metformin Exposure on Survival in a Large National Cohort of Patients with Diabetes and Cirrhosis","volume":"19","author":"Kaplan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Islam, M.M., Poly, T.N., Walther, B.A., Yang, H.C., and Li, Y.C. (2020). Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Cancers, 12.","DOI":"10.3390\/cancers12030671"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Systematic Review","volume":"21","author":"Landi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fonc.2020.00100","article-title":"CyberKnife Stereotactic Body Radiation Therapy as an Effective Treatment for Hepatocellular Carcinoma Patients with Decompensated Cirrhosis","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e0288","DOI":"10.1097\/HC9.0000000000000288","article-title":"Contemporary Applications of Y90 for the Treatment of Hepatocellular Carcinoma","volume":"7","author":"Yu","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","article-title":"Recurrence of Hepatocellular Cancer after Resection: Patterns, Treatments, and Prognosis","volume":"261","author":"Tabrizian","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.14261","article-title":"Temporal Trends, Clinical Patterns and Outcomes of NAFLD-Related HCC in Patients Undergoing Liver Resection over a 20-Year Period","volume":"46","author":"Pais","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2016.066","article-title":"Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma","volume":"49","author":"Jung","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Li, X.S., Li, J.W., Li, H., and Jiang, T. (2020). Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) for Hepatocellular Carcinoma: A Meta-Analysis. Biosci. Rep., 40.","DOI":"10.1042\/BSR20200459"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A Clinical Trial of CTLA-4 Blockade with Tremelimumab in Patients with Hepatocellular Carcinoma and Chronic Hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated Efficacy and Safety Data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"BSR20200459","DOI":"10.1097\/HC9.0000000000000302","article-title":"Efficacy and Safety of Atezolizumab\/Bevacizumab in Patients with HCC after Prior Systemic Therapy: A Global, Observational Study","volume":"7","author":"Joerg","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus Rivoceranib versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): A Randomised, Open-Label, International Phase 3 Study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_127","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/apt.14342","article-title":"Survival after Treatment with Curative Intent for Hepatocellular Carcinoma among Patients with vs without Non-Alcoholic Fatty Liver Disease","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.25536","article-title":"Outcomes of Curative Treatment for Hepatocellular Cancer in Nonalcoholic Steatohepatitis versus Hepatitis C and Alcoholic Liver Disease","volume":"55","author":"Reddy","year":"2012","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.hpb.2021.01.009","article-title":"Outcomes after Curative Therapy for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Review of Current Literature","volume":"23","author":"Chin","year":"2021","journal-title":"Hpb"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.jhepr.2020.100192","article-title":"NAFLD and Liver Transplantation: Disease Burden, Current Management and Future Challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"100668","DOI":"10.1016\/j.jhepr.2022.100668","article-title":"Inevitability of Disease Recurrence after Liver Transplantation for NAFLD Cirrhosis","volume":"5","author":"Villeret","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e065","DOI":"10.1097\/AS9.0000000000000065","article-title":"Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients","volume":"2","author":"Molinari","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/TP.0000000000002043","article-title":"Liver Transplantation for NASH-Related Hepatocellular Carcinoma versus Non-NASH Etiologies of Hepatocellular Carcinoma","volume":"102","author":"Sadler","year":"2018","journal-title":"Transplantation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/liv.15129","article-title":"Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease","volume":"42","author":"Nguyen","year":"2022","journal-title":"Liver Int."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00270-019-02363-x","article-title":"Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis","volume":"43","author":"Young","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"175628482211001","DOI":"10.1177\/17562848221100106","article-title":"Impact of NAFLD on Clinical Outcomes in Hepatocellular Carcinoma Treated with Sorafenib: An International Cohort Study","volume":"15","author":"Howell","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","article-title":"Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150","volume":"165","author":"Espinoza","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1038\/s41598-021-96089-x","article-title":"Efficacy of Lenvatinib for Unresectable Hepatocellular Carcinoma Based on Background Liver Disease Etiology: Multi-Center Retrospective Study","volume":"11","author":"Hiraoka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of Randomized Controlled Trials (2002\u20132020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/259\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:41:26Z","timestamp":1760103686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020259"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020259","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]}}}